10.02.26
Huningue, France, February 10, 2026 – Firalis Molecular Precision, a company specialized in biomarkers and multi-omic analyses for precision medicine, announces its integration into Janvier Group Biosciences, a family-owned group recognized as a leading player in the field of biosciences and preclinical research.
This integration opens new opportunities for Firalis Molecular Precision’s clients, who can now benefit from a more comprehensive range of services, while gaining in responsiveness and synergies thanks to enhanced coordination between teams and technological platforms.
“We are proud to welcome the employees of Firalis Molecular Precision – who have been doing excellent work for several years – into Janvier Group Biosciences. We are also very pleased to be able to offer our partners a new high-value-added activity, in full synergy with our other companies.” Thomas Janvier, CEO of Janvier Group Biosciences
About Janvier Group Biosciences
Since 1960, the Janvier Group has established itself as a global player in bioscience, supporting thousands of international clients in their search for innovative therapies. The group offers an integrated range covering the entire research continuum, from compound discovery to clinical phases, as well as comprehensive bioproduction services and a panel of in vivo and organoid models.
As the last European family-owned group in the sector, Janvier Group Biosciences derives from its independence and long-term vision the ability to make quality and confidentiality its absolute priorities. At every stage, its teams of experts provide dedicated scientific support, transforming the most complex research questions into actionable data that advances therapeutic innovation.
About Firalis Molecular Precision
Firalis Molecular Precision is a leading company in the discovery, validation, and quantification of biomarkers. Founded by Prof. Hüseyin Firat in Huningue in 2016, the company currently has 34 dedicated employees. Firalis Molecular Precision’s key strengths include a state-of-the-art technological platform spanning 2,000 m², a strong quality and regulatory culture (quadruple ISO, CAP, GCLP, robust QMS), a dual European (Huningue, in the heart of BioValley) and American (Cambridge, USA) presence, and a customized approach with scientific support at every stage.
Media Contact
Adeline Bruetsch – Marketing & Communication Manager
Latest posts
